Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06665945 · ClinicalTrials.gov registry record
The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer
A clinical trial of Ovarian Cancer, sponsored by University of Utah.
- Recruiting
- Registry status
- 245
- Enrollment target
- 1
- Study location
NCT06665945 is a study of Ovarian Cancer that is actively recruiting participants, run by University of Utah. The registered enrollment target is 245 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06665945, a study of Ovarian Cancer, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- 245 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer. Using retrospective data, the investigators have developed an approach that appears to accurately classify ovarian cancer with relatively high sensitivity and specificity. The SENTRY Study will build upon these retrospective analyses to prospectively recruit women with ovarian cancer or an ovarian mass (and healthy control women), obtain platelet RNA samples from whole blood, and perform validation analyses to test our hypothesis.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Platelet RNA expression
Study Locations (1)
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2027-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06665945
The ClinicalTrials.gov registry entry for NCT06665945 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (66% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Platelet RNA expression is the first listed.
NCT06665945 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT06665945 about?
NCT06665945 is a clinical study titled "The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer". The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer. Using retrospective data, the investigators have developed an approach that appears to...
What is the current status of trial NCT06665945?
This trial is currently recruiting. The enrollment target is 245 participants. The study started on 2025-04-15. Estimated completion is 2027-12-01.
What conditions does trial NCT06665945 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT06665945?
The interventions under investigation include: Platelet RNA expression (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06665945?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06665945 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.